# Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Source: https://onco.cc/trials/nct05751798/  
OnCo record `nct05751798` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OSE2101 in non-small-cell lung cancer and small-cell lung cancer, run by OSE Immunotherapeutics, now recruiting.

## Summary

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05751798 by OSE Immunotherapeutics, with 41 participants planned, started 2022-12-20 and due to reach its primary completion in 2029-12. Interventions recorded: Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg, Part B: OSE-279 600 mg and OSE2101, Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive. Conditions listed: Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05751798
- Phase: 1/2
- Setting: A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas
- Sponsor: OSE Immunotherapeutics
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT05751798: https://clinicaltrials.gov/study/NCT05751798

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [OSE2101](https://onco.cc/drugs/ose2101/)
- companies: [OSE Immunotherapeutics](https://onco.cc/companies/ose-immunotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05751798.json